Novel immunoediting mechanisms via somatic mutations

• Project/Area Number: 19K22574
• Research Category: Grant-in-Aid for Challenging Research (Exploratory)
• Allocation Type: Multi-year Fund
• Review Section: Medium-sized Section 50:Oncology and related fields
• Research Institution: Chiba Cancer Center (Research Institute)
• Principal Investigator: Togashi Yosuke 千葉県がんセンター(研究所), がん治療開発グループ 細胞治療開発研究部, 部長代理 (80758326)
• Project Period (FY): 2019-06-28 – 2021-03-31
• Project Status: Completed (Fiscal Year 2020)
• Budget Amount: ¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000); Fiscal Year 2020: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000); Fiscal Year 2019: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
• Keywords: がん免疫編集 / 腫瘍免疫 / ネオ抗原

Outline of Research at the Start

発がん過程で、がんは抗腫瘍免疫応答から逃れるため免疫制御機構を巧みに利用している(「がん免疫編集」)。体細胞変異数が多いと異物として認識される抗原（ネオ抗原）も多いため免疫原性が高くがん免疫療法の効果が高いとされている。しかし予備検討で体細胞変異数が極端に多い場合には免疫応答が抑制され、特定の免疫抑制シグナルの遺伝子セットの発現が高いことを見出した。そこで本研究課題では体細胞変異数が極端に多いが免疫応答が抑制されている症例でのT細胞の実際のネオ抗原への反応や、原因シグナルやゲノム異常を明らかにし、従来の「がん免疫編集」に加えた新たな免疫編集機構の提唱を目指す。

Outline of Final Research Achievements

Cancer cells with high tumor mutation burden (TMB) can have a more malignant phenotype, but strong antitumor immunity can be also induced by high TMB. Here, we have found that a fraction of patients has non-inflamed tumor microenvironment despite high TMB due to some signaling pathways related to the malignant phenotype and we could validate several pathways using mouse models. From these findings, novel immunoediting mechanisms via somatic mutations is proposed, and we should consider not only just simple TMB but also the quality.

Academic Significance and Societal Importance of the Research Achievements

従来の「がん免疫編集」に加えて、がんが悪性度に関わるようなシグナルを巧みに利用して免疫系から逃れているという新たながん免疫編集を明らかにした。そのような悪性度に関わるシグナルもいくつか同定し、それらはがん免疫療法の治療標的になる可能性があり、今後のバイオマーカーや併用療法としての新たな治療開発に繋がるデータである。

Research Products

• [Journal Article] Aging, cancer, and antitumor immunity (2021)
  • Author(s): Ikeda Hideki、Togashi Yosuke
  • Journal Title: International Journal of Clinical Oncology Volume: Epub Issue: 2 Pages: 316-322
  • DOI: 10.1007/s10147-021-01913-z
  • Peer Reviewed
• [Journal Article] Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer (2021)
  • Author(s): Inamori Koji、Togashi Yosuke、Fukuoka Shota、Akagi Kiwamu、Ogasawara Kouetsu、Irie Takuma、Motooka Daisuke、Kobayashi Yoichi、Sugiyama Daisuke、Kojima Motohiro、Shiiya Norihiko、Nakamura Shota、Maruyama Shoichi、Suzuki Yutaka、Ito Masaaki、Nishikawa Hiroyoshi
  • Journal Title: JCI Insight Volume: 8 Issue: 9 Pages: 137365-137365
  • DOI: 10.1172/jci.insight.137365
  • Peer Reviewed / Open Access
• [Journal Article] HSP90 inhibition overcomes EGFR amplification-induced resistance to third-generation EGFR-TKIs (2021)
  • Author(s): Watanabe S, Goto Y, Yasuda H, Kohno T, Motoi N, Ohe Y, Nishikawa H, Kobayashi SS, Kuwano K, Togashi Y.
  • Journal Title: Thoracic Cancer Volume: 12 Issue: 5 Pages: 631-42
  • DOI: 10.1111/1759-7714.13839
  • Peer Reviewed / Open Access
• [Journal Article] Potentiality of multiple modalities for single-cell analyses to evaluate the tumor microenvironment in clinical specimens (2021)
  • Author(s): Kashima Yukie、Togashi Yosuke、Fukuoka Shota、et al.
  • Journal Title: Scientific Reports Volume: 11 Issue: 1 Pages: 341-341
  • DOI: 10.1038/s41598-020-79385-w
  • Peer Reviewed / Open Access
• [Journal Article] Vaginal Transmission of Cancer from Mothers with Cervical Cancer to Infants (2021)
  • Author(s): Arakawa A, Ichikawa H, Kubo T, Motoi N, Kumamoto T, Nakajima M, Yonemori K, Noguchi E, Sunami K, Shiraishi K, Kakishima H, Yoshida H, Hishiki T, Kawakubo N, Kuroda T, Kiyokawa T, Yamada K, Yanaihara N, et al, and Kohno T, Ogawa C.
  • Journal Title: New England Journal of Medicine Volume: 384 Issue: 1 Pages: 42-50
  • DOI: 10.1056/nejmoa2030391
  • Peer Reviewed / Open Access
• [Journal Article] Heterogeneity in congenital melanocytic nevi contributes to multicentric melanomagenesis (2020)
  • Author(s): Honobe Akiko、Sakai Kazuko、Togashi Yosuke、Ohnuma Takehiro、Kawamura Tatsuyoshi、Nishio Kazuto、Inozume Takashi
  • Journal Title: Journal of Dermatological Science Volume: 100 Issue: 3 Pages: 217-219
  • DOI: 10.1016/j.jdermsci.2020.09.004
  • Peer Reviewed
• [Journal Article] The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies (2020)
  • Author(s): Kumagai S,Togashi Y,Kamada T,Sugiyama E,Nishinakamura H,Takeuchi Y,Vitaly K,Itahashi K,Maeda Y,Matsui S,Shibahara T,Yamashita Y,Irie T,Tsuge A,Fukuoka S,Kawazoe A,Udagawa H,Kirita K,Aokage K,Ishii G,Kuwata T,Nakama K,Kawazu M,Ueno T,Yamazaki N,Goto K,Tsuboi M,Mano H,Doi T,Shitara K,Nishikawa H
  • Journal Title: Nature Immunology Volume: 21 Issue: 11 Pages: 1346-1358
  • DOI: 10.1038/s41590-020-0769-3
  • Peer Reviewed / Open Access
• [Journal Article] Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial (2020)
  • Author(s): Hayashi, H. Takiguchi, Y. Minami, H. Akiyoshi, K. Segawa, Y. Ueda, H. Iwamoto, Y. Kondoh, C. Matsumoto, K. Takahashi, S. Yasui, H. Sawa, T. Onozawa, Y. Chiba, Y. Togashi, Y. Fujita, Y. Sakai, K. Tomida, S. Nishio, K. Nakagawa, K.
  • Journal Title: JAMA Oncol Volume: 6 Issue: 12 Pages: 1931-1938
  • DOI: 10.1001/jamaoncol.2020.4643
  • Peer Reviewed / Open Access
• [Journal Article] The critical role of CD4+ T cells in PD-1 blockade against MHC-II?expressing tumors such as classic Hodgkin lymphoma (2020)
  • Author(s): Nagasaki Joji、Togashi Yosuke、Sugawara Takeaki、Itami Makiko、Yamauchi Nobuhiko、Yuda Junichiro、Sugano Masato、Ohara Yuuki、Minami Yosuke、Nakamae Hirohisa、Hino Masayuki、Takeuchi Masahiro、Nishikawa Hiroyoshi
  • Journal Title: Blood Advances Volume: 4 Issue: 17 Pages: 4069-4082
  • DOI: 10.1182/bloodadvances.2020002098
  • Peer Reviewed / Open Access
• [Journal Article] Enhanced Tumor Response to Radiotherapy After PD-1 Blockade in Metastatic Gastric Cancer (2020)
  • Author(s): Sasaki A, Nakamura Y, Togashi Y, Kuno H, Hojo H, Kageyama S, Nakamura N, Takashima K, Kadota T, Yoda Y, Mishima S, Sawada K, Kotani D, Kawazoe A, Kuboki Y, Taniguchi H, Kojima T, Doi T, Yoshino T, Yano T, Kobayashi T, Akimoto T, Nishikawa H, Shitara K.
  • Journal Title: Gastric Cancer Volume: - Issue: 5 Pages: 893-903
  • DOI: 10.1007/s10120-020-01058-4
  • NAID: 40022329655
  • Peer Reviewed
• [Journal Article] Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial) (2020)
  • Author(s): Kawazoe Akihito、Kuboki Yasutoshi、Shinozaki Eiji、Hara Hiroki、Nishina Tomohiro、Komatsu Yoshito、Yuki Satoshi、Wakabayashi Masashi、Nomura Shogo、Sato Akihiro、Kuwata Takeshi、Kawazu Masahito、Mano Hiroyuki、Togashi Yosuke、Nishikawa Hiroyoshi、Yoshino Takayuki
  • Journal Title: Clinical Cancer Research Volume: 26 Issue: 22 Pages: 5887-5894
  • DOI: 10.1158/1078-0432.ccr-20-1803
  • Peer Reviewed / Open Access
• [Journal Article] An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells (2020)
  • Author(s): Shogo Kumagai, Yosuke Togashi, Chika Sakai, Akihito Kawazoe, Masahito Kawazu, Toshihide Ueno, Eiichi Sato, Takeshi Kuwata, Takahiro Kinoshita, Masami Yamamoto, Sachiyo Nomura, Tetsuya Tsukamoto, Hiroyuki Mano, Kohei Shitara, Hiroyoshi Nishikawa
  • Journal Title: Immunity Volume: 14 Issue: 1 Pages: 187-203
  • DOI: 10.1016/j.immuni.2020.06.016
  • NAID: 120006952281
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Association between the mutational smoking signature and the immune microenvironment in lung adenocarcinoma (2020)
  • Author(s): Sato Kei、Mimaki Sachiyo、Yamashita Riu、Togashi Yosuke、Naito Tomoyuki、Udagawa Hibiki、Katsumata Shinya、Nakasone Shoko、Miyoshi Tomohiro、Tane Kenta、Aokage Keiju、Sugano Masato、Kojima Motohiro、Fujii Satoshi、Kuwata Takeshi、Ochiai Atsushi、Goto Koichi、Tsuboi Masahiro、Tsuchihara Katsuya、Ishii Genichiro
  • Journal Title: Lung Cancer Volume: 147 Pages: 12-20
  • DOI: 10.1016/j.lungcan.2020.06.029
  • Peer Reviewed
• [Journal Article] Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603) (2020)
  • Author(s): Fukuoka Shota、Hara Hiroki、Takahashi Naoki、Kojima Takashi、Kawazoe Akihito、Asayama Masako、Yoshii Takako、Kotani Daisuke、Tamura Hitomi、Mikamoto Yuichi、Hirano Nami、Wakabayashi Masashi、Nomura Shogo、Sato Akihiro、Kuwata Takeshi、Togashi Yosuke、Nishikawa Hiroyoshi、Shitara Kohei
  • Journal Title: Journal of Clinical Oncology Volume: 38 Issue: 18 Pages: 2053-2061
  • DOI: 10.1200/jco.19.03296
  • Peer Reviewed
• [Journal Article] TENERGY: Multicenter Phase II Study of Atezolizumab Monotherapy Following Definitive Chemoradiotherapy With 5-FU Plus Cisplatin in Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma (2020)
  • Author(s): Bando H, Kotani D, Tsushima T, Hara H, Kadowaki S, Kato K, Chin K, Yamaguchi K, Kageyama SI, Hojo H, Nakamura M, Tachibana H, Wakabayashi M, Fukutani M, Togashi Y, Fuse N, Nishikawa H, Kojima T.
  • Journal Title: BMC Cancer Volume: 20 Issue: 1 Pages: 336-336
  • DOI: 10.1186/s12885-020-06716-5
  • Peer Reviewed / Open Access
• [Journal Article] The potential application of PD-1 blockade therapy for early-stage biliary tract cancer. (2020)
  • Author(s): Umemoto K, Togashi Y, Arai Y, Nakamura H, Takahashi S, Tanegashima T, Kato M, Nishikawa T, Sugiyama D, Kojima M, Gotohda N, Kuwata T, Ikeda M, Shibata T, Nishikawa H.
  • Journal Title: Int Immunol. Volume: 32 Issue: 4 Pages: 273-281
  • DOI: 10.1093/intimm/dxz080
  • Peer Reviewed / Open Access
• [Journal Article] Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non?small cell lung cancer (2020)
  • Author(s): Sugiyama Eri、Togashi Yosuke、Takeuchi Yoshiko、Shinya Sayoko、Tada Yasuko、Kataoka Keisuke、Tane Kenta、Sato Eiichi、Ishii Genichiro、Goto Koichi、Shintani Yasushi、Okumura Meinoshin、Tsuboi Masahiro、Nishikawa Hiroyoshi
  • Journal Title: Science Immunology Volume: 5 Issue: 43 Pages: 3937-3937
  • DOI: 10.1126/sciimmunol.aav3937
  • NAID: 120006845852
  • Peer Reviewed / Open Access
• [Journal Article] Immune suppression by PD-L2 against spontaneous and treatment-related antitumor immunity (2019)
  • Author(s): Tanegashima Tokiyoshi、Togashi Yosuke、Azuma Koichi、Kawahara Akihiko、Ideguchi Ko、Sugiyama Daisuke、Kinoshita Fumio、Akiba Jun、Kashiwagi Eiji、Takeuchi Ario、Irie Takuma、Tatsugami Katsunori、Hoshino Tomoaki、Eto Masatoshi、Nishikawa Hiroyoshi
  • Journal Title: Clinical Cancer Research Volume: In press Issue: 15 Pages: 4808-4819
  • DOI: 10.1158/1078-0432.ccr-18-3991
  • Peer Reviewed
• [Journal Article] Clinical and immune profiling for cancer of unknown primary site. (2019)
  • Author(s): Haratani K, Hayashi H, Takahama T, Nakamura Y, Tomida S, Yoshida T, Chiba Y, Sawada T, Sakai K, Fujita Y, Togashi Y, Tanizaki J, Kawakami H, Ito A, Nishio K, Nakagawa K
  • Journal Title: Journal for immunotherapy of cancer Volume: 7 Issue: 1 Pages: 251-251
  • DOI: 10.1186/s40425-019-0720-z
  • Peer Reviewed / Open Access
• [Journal Article] Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids (2019)
  • Author(s): Tokunaga Akihiro、Sugiyama Daisuke、Maeda Yuka、Warner Allison Betof、Panageas Katherine S.、Ito Sachiko、Togashi Yosuke、Sakai Chika、Wolchok Jedd D.、Nishikawa Hiroyoshi
  • Journal Title: Journal of Experimental Medicine Volume: 216 Issue: 12 Pages: 2701-2713
  • DOI: 10.1084/jem.20190738
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer (2019)
  • Author(s): Kamada Takahiro、Togashi Yosuke、Tay Christopher、Ha Danbee、Sasaki Akinori、Nakamura Yoshiaki、Sato Eiichi、Fukuoka Shota、Tada Yasuko、Tanaka Atsushi、Morikawa Hiromasa、Kawazoe Akihito、Kinoshita Takahiro、Shitara Kohei、Sakaguchi Shimon、Nishikawa Hiroyoshi
  • Journal Title: Proceedings of the National Academy of Sciences Volume: In press Issue: 20 Pages: 9999-10008
  • DOI: 10.1073/pnas.1822001116
  • Peer Reviewed / Open Access
• [Presentation] The Future of Immunotherapy (2021)
  • Author(s): Yosuke Togashi
  • Organizer: 2021 Targeted Therapy of Lung Cancer Meeting
  • Int'l Joint Research / Invited
• [Presentation] Clonal evolution in the tumor microenvironment (2021)
  • Author(s): Yosuke Togashi
  • Organizer: 第18回日本臨床腫瘍学会学術集会
  • Invited
• [Presentation] Phase II Trial of Site-Specific Treatment Based on Gene Expression and Mutation Profiling by next generation sequencing (NGS) for Patients (pts) With Cancer of Unknown Primary Site (CUP) (2021)
  • Author(s): Makoto Arai, Hidetoshi Hayashi, Hironobu Minami, Yuichi Takiguchi, Satomi Watanabe, Masanori Toyoda, Kohei Akiyoshi, Yoshihiko Segawa, Hiroki Ueda, Yasuo Iwamoto, Jun Masuda, Hirohumi Mukai, Toshio Kubo, Yosuke Togashi, Kazuko Sakai, Yoshihiko Fujita, Shuta Tomida, Yasutaka Chiba, Kazuto Nishio, and Kazuhiko Nakagawa.
  • Organizer: 第18回日本臨床腫瘍学会学術集会
• [Presentation] The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphoma. (2021)
  • Author(s): Joji Nagasaki1, Yosuke Togashi, Takeaki Sugawara, Makiko Itami, Nobuhiko Yamauchi, Junichiro Yuda, Sugano Masato, Ohara Yuuki, Yosuke Minami, Hirohisa Nakamae, Masayuki Hino, Masahiro Takeuchi, Hiroyoshi Nishikawa.
  • Organizer: 第18回日本臨床腫瘍学会学術集会
• [Presentation] Heterogeneity in congenital melanocytic nevi contributes to muliticentric melanomagenesis. (2021)
  • Author(s): Takashi Inozume, Akiko Honobe, Kazuko Sakai, Yosuke Togashi, Takehiro Ohnura, Tatsuyoshi Kawamura, Kazuto Nishio
  • Organizer: 第18回日本臨床腫瘍学会学術集会
• [Presentation] Efficacy Predictors of Preoperative CRT and Consolidation Nivolumab in Patients with Locally Advanced Rectal Cancer (2021)
  • Author(s): Koji Inamori, Yosuke Togashi, Hideaki Bando, Yuichiro Tsukada, Shota Fukuoka,Yutaka Suzuki, Daisuke Kotani, Motohiro Kojima, Makoto Fukui, Satoshi Yuki, Yoshito Komatsu, Shigenori Homma, Akinobu Taketomi, Mamoru Uemura, Takeshi Kato, Masaaki Ito, Hiroyoshi Nishikawa, Takayuki Yoshino.
  • Organizer: 第18回日本臨床腫瘍学会学術集会
• [Presentation] TIGIT/CD155 axis mediates resistance to immunotherapies in inflamed tumors. (2021)
  • Author(s): Shusuke Kawashima, Takashi Inozume, Masahito Kawazu, Etsuko Tanji, Akiko Honobe, Takehiro Ohnuma, Tatsuyoshi Kawamura, Hiroyuki Matsue, Yosuke Togashi.
  • Organizer: 第18回日本臨床腫瘍学会学術集会
• [Presentation] Emerging biomarker for immunotherapy in head and neck cancer (2021)
  • Author(s): Yosuke Togashi
  • Organizer: 第18回日本臨床腫瘍学会学術集会
  • Invited
• [Presentation] Translational Research of VOLTAGE-A: Efficacy Predictors of Preoperative Chemoradiotherapy and Consolidation Nivolumab in Patients with both Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal Cancer (2021)
  • Author(s): Koji Inamori, Yosuke Togashi, Hideaki Bando, Yuichiro Tsukada, Shota Fukuoka, Ayako Suzuki, Yutaka Suzuki, Daisuke Kotani, Motohiro Kojima, Makoto Fukui, Satoshi Yuki, Yoshito Komatsu, Shigenori Homma, Akinobu Taketomi, Mamoru Uemura, Takeshi Kato, Masaaki Ito, Hiroyoshi Nishikawa, Takayuki Yoshino.
  • Organizer: ASCO-GI2021
  • Int'l Joint Research
• [Presentation] 腫瘍に発現するPD-L2の免疫抑制機能について (2020)
  • Author(s): 種子島 時祥, 冨樫 庸介, 東 公一, 入江 拓磨, 木下 史生, 柏木 英志, 武内 在雄, 立神 勝則, 江藤 正俊, 西川 博嘉
  • Organizer: 第108回日本泌尿器科学総会
• [Presentation] PD-L2による、自発的・治療関連抗腫瘍免疫に対する免疫抑制機能 (2020)
  • Author(s): 種子島 時祥, 冨樫 庸介, 江藤 正俊, 西川 博嘉
  • Organizer: 第72回西日本泌尿器科学総会
• [Presentation] Translational Research using Clinical Samples in Cancer Immunology (2020)
  • Author(s): Yosuke Togashi
  • Organizer: 第79回日本癌学会学術総会
  • Invited
• [Presentation] 免疫チェックポイント阻害剤と制御性T細胞 (2020)
  • Author(s): 冨樫庸介
  • Organizer: 第24回日本がん分子標的治療学会
  • Invited
• [Presentation] 免疫チェックポイント阻害剤を含む併用療法におけるバイオマーカー (2020)
  • Author(s): 冨樫庸介
  • Organizer: 第60回日本呼吸器学会学術講演会
  • Invited
• [Presentation] Cancer immunogenomics (2020)
  • Author(s): Yosuke Togashi
  • Organizer: KSMO and JSMO Joint Symposium
  • Int'l Joint Research / Invited
• [Presentation] Translational Research for Future Immunotherapy (2020)
  • Author(s): 冨樫庸介
  • Organizer: 第92回日本胃癌学会総会
  • Invited
• [Presentation] Translational research of voltage-A1: Efficacy predictors of preoperative chemoradiotherapy and subsequent nivolumab monotherapy in patients with microsatellite-stable locally advanced rectal cancer (2020)
  • Author(s): Koji Inamori, Yosuke Togashi, Hideaki Bando, Yuichiro Tsukada, Shota Fukuoka, Ayako Suzuki, Yutaka Suzuki, Daisuke Kotani, Motohiro Kojima, Makoto Fukui, Satoshi Yuki, Yoshito Komatsu, Shigenori Homma, Akinobu Taketomi, Mamoru Uemura, Takeshi Kato, Masaaki Ito, Hiroyoshi Nishikawa, Takayuki Yoshino
  • Organizer: ASCO2020
  • Int'l Joint Research
• [Presentation] Short-Term Results of VOLTAGE-A: Nivolumab Monotherapy and Subsequent Radical Surgery Following Preoperative Chemoradiotherapy in Patients with Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal Cancer. (2020)
  • Author(s): Satoshi Yuki, Hideaki Bando, Yuichiro Tsukada, Koji Inamori, Yoshito Komatsu, Shigenori Homma, Mamoru Uemura, Takeshi Kato, Daisuke Kotani, Shota Fukuoka, Naoki Nakamura, Makoto Fukui, Masashi Wakabayashi, Motohiro Kojima, Yosuke Togashi, Akihiro Sato, Hiroyoshi Nishikawa, Masaaki Ito, Takayuki Yoshino
  • Organizer: ASCO2020
  • Int'l Joint Research
• [Presentation] Predictive Biomarkers in Cancer Immunotherapy (2019)
  • Author(s): Togashi Yosuke
  • Organizer: 第17回日本臨床腫瘍学会学術集会
  • Invited
• [Presentation] Single cell analysis for cancer immunology (2019)
  • Author(s): Togashi Yosuke
  • Organizer: 第78回日本癌学会学術総会
  • Invited
• [Presentation] The role of soluble immune-checkpoint factors in advanced NSCLC (2019)
  • Author(s): 林秀敏、茶本健司、冨樫庸介、中川和彦、本庶佑
  • Organizer: 第60回日本肺癌学会学術集会
• [Presentation] EGFR-TKIによる腫瘍微小環境の免疫状態の変化 (2019)
  • Author(s): 多根健太、宇田川響、桐田佳輔、杉山栄里、三好智裕、青影圭樹、後藤功一、坪井正博、冨樫庸介、西川博嘉
  • Organizer: 第60回日本肺癌学会学術集会
• [Presentation] 腫瘍に発現するPD-L2の免疫抑制機能について (2019)
  • Author(s): 種子島時祥 冨樫庸介 東公一 江藤正俊 西川博嘉
  • Organizer: 第32回バイオセラピー学会
• [Presentation] A novel regulatory T cell-targeted immunotherapy via meddling the crucial signal by HSP90 inhibitors (2019)
  • Author(s): Ayaka Tsuge，Yosuke Togashi，Hiroyoshi Nishikawa
  • Organizer: 第48回日本免疫学会学術集会
• [Presentation] A Novel Regulatory T Cell-Targeted Immunotherapy by targeting their Crucial Signal by HSP90 Inhibitors (2019)
  • Author(s): Ayaka Tsuge，Yosuke Togashi，Hiroyoshi Nishikawa
  • Organizer: SITC
  • Int'l Joint Research
• [Presentation] Multiple modalities of single cell analyses to evaluate the tumor microenvironment in clinical specimens (2019)
  • Author(s): Yukie Kashima, Shota Fukuoka, Yosuke Togashi, Takahiro Kamada, Ayako Suzuki, Yoshiaki Nakamura, Kohei Shitara, Akihiro Ohashi, Taku Yoshida, Naofumi Taoka, Tatsuya Kawase, Teiji Wada, Kocihiro Inaki, Masataka Chihara, Yutaka Suzuki, Katsuya Tsuchihara, Susumu S Kobayashi, Hiroyoshi Nishikawa and Toshihiko Doi
  • Organizer: EORTC-AACR
  • Int'l Joint Research
• [Presentation] Immune suppression by PD-L2 against spontaneous and treatment-related antitumor immunity (2019)
  • Author(s): Tanegashima Tokiyoshi, Togashi Yosuke, Azuma Kimitoshi, Eto Masatoshi, Nishikawa Hiroyoshi
  • Organizer: 第78回日本癌学会学術総会
• [Presentation] Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): an open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603) (2019)
  • Author(s): Shota Fukuoka, Hiroki Hara, Naoki Takahashi, Takashi Kojima, Akihito Kawazoe, Masako Asayama, Takako Yoshii, Daisuke Kotani, Hitomi Tamura, Yuichi Mikamoto, Ayako Sugama, Masashi Wakabayashi, Shogo Nomura, Akihiro Sato, Yosuke Togashi, Hiroyoshi Nishikawa, Kohei Shitara
  • Organizer: 第17回日本臨床腫瘍学会学術集会
• [Presentation] Clinical utility of precision immunoprofiling and monitoring tumor microenvironment by flowcytometry and CyTOF in advanced NSCLC treated with atezolizumab; results from a phase II study for biomarker analysis (EPOC1702) (2019)
  • Author(s): Keisuke Kirita, Eri Sugiyama, Yosuke Togashi, Hibiki Udagawa, Shingo Matsumoto, Kiyotaka Yoh, Seiji Niho, Hiroyoshi Nishikawa and Koichi Goto
  • Organizer: 第17回日本臨床腫瘍学会学術集会
• [Presentation] The PD-1 expression balance between effector and regulatory T cell predicts the clinical efficacy of PD-1 blockade therapies (2019)
  • Author(s): Yosuke Togashi, Takahiro Kamada, Eri Sugiyama, Shota Fukuoka, Akihito Kawazoe, Hibiki Udagawa, Keisuke Kirita, Koichi Goto, Masahiro Tsuboi, Toshihiko Doi, Kohei Shitara, Hiroyoshi Nishikawa
  • Organizer: 第17回日本臨床腫瘍学会学術集会
• [Presentation] Novel concept of EGFR-signal contribution to unique immunological status of the tumor microenvironment in EGFR-mutated NSCLC (2019)
  • Author(s): Eri Sugiyama, Yosuke Togashi, Yoshiko Takeuchi, Sayoko Shinya, Yasuko Tada, Keisuke Kataoka, Kenta Tane, Genichiro Ishii, Koichi Goto, Yasushi Shintani, Meinoshin Okumura, Masahiro Tsuboi, Hiroyoshi Nishikawa
  • Organizer: 第17回日本臨床腫瘍学会学術集会
• [Presentation] Combination of triplet soluble immune-checkpoint factors as a complementary biomarker for the efficacy of nivolumab (nivo) in advanced non-small cell lung cancer (NSCLC) patients (pts) (2019)
  • Author(s): Hidetoshi Hayashi, Kenji Chamoto, Yosuke Togashi, Kazuya Fukuoka, Ryusuke Hatae, Megumi Goto, Yasutaka Chiba, Junko Tanizaki,1,6 Koji Haratani, Takayuki Takahama, Kaoru Tanaka, Masayuki Takeda, Kazuko Sakai, Keiko Higuchi, Hitoshi Uga, Kazuto Nishio, Kazuhiko Nakagawa, Tasuku Honjo
  • Organizer: 第17回日本臨床腫瘍学会学術集会
• [Presentation] Efficacy of Radiotherapy to Primary Tumor After Nivolumab Treatment in Patients with Advanced Gastric Cancer (2019)
  • Author(s): Akinori Sasaki, Yoshiaki Nakamura, Hirofumi Kuno, Yosuke Togashi, Hidehiro Hojo, Kenji Takashima, Tomohiro Kadota, Saori Mishima, Daisuke Kotani, Akihito Kawazoe, Yasutoshi Kuboki, Hiroya Taniguchi,Takayuki Yoshino, Tatsushi Kobayashi, Hiroyoshi Nishikawa, Naoki Nakamura, Tomonori Yano, Kohei Shitara
  • Organizer: 第17回日本臨床腫瘍学会学術集会
• [Presentation] TENERGY: Multicenter Phase II Study of Atezolizumab Monotherapy Following Definitive Chemoradiotherapy with 5-FU plus Cisplatin in Patients with Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma (2019)
  • Author(s): Hideaki Bando, Daisuke Kotani, Takahiro Tsushima, Hiroki Hara, Shigenori Kadowaki, Ken Kato, Keisho Chin, Kensei Yamaguchi, Shun-ichiro Kageyama, Hidehiro Hojo, Shogo Nomura, Miki Fukutani, Yosuke Togashi, Nozomu Fuse, Hiroyoshi Nishikawa, and Takashi Kojima
  • Organizer: ASCO Annual Meeting
  • Int'l Joint Research
• [Presentation] Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): an open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603) (2019)
  • Author(s): Shota Fukuoka, Hiroki Hara, Naoki Takahashi, Takashi Kojima, Akihito Kawazoe, Masako Asayama, Takako Yoshii, Daisuke Kotani, Hitomi Tamura, Yuichi Mikamoto, Ayako Sugama, Masashi Wakabayashi, Shogo Nomura, Akihiro Sato, Yosuke Togashi, Hiroyoshi Nishikawa, Kohei Shitara
  • Organizer: ASCO Annual Meeting
  • Int'l Joint Research
• [Presentation] VOLTAGE: Investigator-initiated Clinical Trial of Nivolumab Monotherapy and Subsequent Radical Surgery Following Preoperative Chemoradiotherapy in Patients with Microsatellite Stable Locally Advanced Rectal Cancer (2019)
  • Author(s): Takayuki Yoshino, Hideaki Bando, Yuichiro Tsukada, Koji Inamori, Satoshi Yuki, Yoshito Komatsu, Shigenori Homma, Mamoru Uemura, Takeshi Kato, Daisuke Kotani, Shota Fukuoka, Yosuke Togashi, Akihiro Sato, Hiroyoshi Nishikawa, Masaaki Ito
  • Organizer: ASCO Annual Meeting
  • Int'l Joint Research
• [Presentation] An Open Label Phase I Study to Evaluate the Safety and Efficacy of OBP-301 With Pembrolizumab in Patients With Advanced Solid Tumors (EPOC1505) (2019)
  • Author(s): Takashi Kojima, Toshiyoshi Fujiwara, Yasuhiro Shirakawa, Keisuke Hori, Hiromi Ono, Masako Nakamoto, Hiromi Hasegawa, Nami Hirano, Masashi Wakabayashi, Shogo Nomura, Yosuke Togashi, Hiroyoshi Nishikawa, Akihiro Sato, Atsushi Ohtsu, Toshihiko Doi
  • Organizer: AACR Annual Meeting
  • Int'l Joint Research
• [Presentation] The association of genomic features and immunosuppression in gastric cancer (2019)
  • Author(s): Shogo Kumagai, Yosuke Togashi, Kohei Shitara, Takahiro Kinoshita, Katsuya Tsuchihara, Hiroyoshi Nishikawa
  • Organizer: AACR Annual Meeting
  • Int'l Joint Research
• [Presentation] The secondary immune selection is the dominant mechanism for acquired resistance against adoptive cell therapy (2019)
  • Author(s): Takahiro Kamada, Yosuke Togashi, Yoshihiro Ohue, Hiroyoshi Nishikawa
  • Organizer: AACR Annual Meeting
  • Int'l Joint Research
• [Book] 実験医学増刊（シングルセルゲノミクスで見える新しい生命象） (2019)
  • Author(s): 鈴木穣、渡辺亮（分担執筆：冨樫庸介）
  • Total Pages: 6
  • Publisher: 羊土社
• [Book] 実験医学増刊（がん免疫療法の個別化を支える最新・腫瘍免疫学） (2019)
  • Author(s): 河上裕（分担執筆：冨樫庸介）
  • Total Pages: 8
  • Publisher: 羊土社